The estimated Net Worth of Veer Bhavnagri is at least $4.27 Million dollars as of 13 February 2023. Mr Bhavnagri owns over 3,000 units of Allogene Therapeutics Inc stock worth over $1,681,040 and over the last 4 years he sold ALLO stock worth over $1,946,646. In addition, he makes $646,885 as Gen. Counsel & Compliance Officer at Allogene Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr Bhavnagri ALLO stock SEC Form 4 insiders trading
Mr has made over 17 trades of the Allogene Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of ALLO stock worth $20,550 on 13 February 2023.
The largest trade he's ever made was exercising 51,500 units of Allogene Therapeutics Inc stock on 17 December 2020 worth over $116,905. On average, Mr trades about 11,006 units every 46 days since 2020. As of 13 February 2023 he still owns at least 577,677 units of Allogene Therapeutics Inc stock.
You can see the complete history of Mr Bhavnagri stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Veer Bhavnagri biography
Veer Bhavnagri is the Gen. Counsel & Compliance Officer at Allogene Therapeutics Inc.
What is the salary of Mr Bhavnagri?
As the Gen. Counsel & Compliance Officer of Allogene Therapeutics Inc, the total compensation of Mr Bhavnagri at Allogene Therapeutics Inc is $646,885. There are 13 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
How old is Mr Bhavnagri?
Mr Bhavnagri is 38, he's been the Gen. Counsel & Compliance Officer of Allogene Therapeutics Inc since . There are 19 older and 1 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
Insiders trading at Allogene Therapeutics Inc
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun, and Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
What does Allogene Therapeutics Inc do?
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
What does Allogene Therapeutics Inc's logo look like?
Complete history of Mr Bhavnagri stock trades at Allogene Therapeutics Inc
Allogene Therapeutics Inc executives and stock owners
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Chang,
President, Chief Executive Officer, Co-Founder, Director -
Rafael Amado,
Executive Vice President - Research and Development, Chief Medical Officer -
Arie Belldegrun,
Executive Chairman of the Board -
Eric Schmidt,
Chief Financial Officer -
Alison Moore,
Chief Technical Officer -
Dr. David D. Chang M.D., Ph.D.,
Co-Founder, Pres, CEO & Director -
Joshua Kazam,
Co-Founder, Director -
Dr. Rafael G. Amado M.D.,
Exec. VP of R&D -
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.,
Co-Founder & Exec. Chairman -
Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS,
Co-Founder & Exec. Chairman -
Dr. Rafael G. Amado,
Chief Medical Officer and Exec. VP of R&D -
Dr. Alison Moore Ph.D.,
Chief Technical Officer -
Dr. Eric Thomas Schmidt Ph.D.,
Chief Financial Officer -
Veer Bhavnagri,
Gen. Counsel & Compliance Officer -
Franz Humer,
Independent Director -
Deborah Messemer,
Independent Director -
Owen Witte,
Independent Director -
Joshua A. Kazam,
Co-Founder & Director -
Veer Bhavnagri,
Chief Compliance Officer, General Counsel -
Todd Sisitsky,
Independent Director -
John DeYoung,
Independent Director -
David Bonderman,
Lead Independent Director -
Stephen Cheng,
Chief Information Officer -
David M. Tanen J.D.,
Sec. -
Christine Cassiano,
Chief Communications Officer -
Barbra Sasu,
Chief Scientific Officer -
Timothy L. Moore,
Chief Technical Officer -
Yinlin Jack Chen,
SVP, Finance -
Inc Pfizer,
10% owner -
Earl Martin Douglas,
SVP, General Counsel -
Elizabeth A. Barrett,
-
Vicki L Sato,
-
Equity Holdings 2 B.V. Pf,
10% owner -
Stephen Mayo,
-
Zachary Roberts,
EVP of R&D -
Lillian Smith,
VP, Corporate Counsel -
Geoffrey M. Parker,
CHIEF FINANCIAL OFFICER